In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tercica rhIGF-1 short stature study

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Tercica began a Phase IIIb study of its recombinant human insulin-like growth factor-1 (rhIGF-1) in children with short stature caused by primary IGF-1 deficiency Oct. 28. The two-year study, which "will be the basis of a future regulatory filing," will enroll 160 pre-pubertal children whose height and IGF-1 levels are more than two standard deviations below normal. Primary endpoint is change in height SD over one year. Tercica plans to file a separate rhIGF-1 NDA in "early 2005" for severe primary IGF deficiency, a subset of patients whose height and serum IGF-1 levels are more than three standard deviations below normal. Thirty-thousand children have primary IGFD in the U.S., of which 6,000 have the severe form, Tercica estimates...

You may also be interested in...



Podcast: Scrip’s Asia Team Dissects Pharma’s Response To Coronavirus

Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.

Lilly’s Cyramza Wins Slim Nod, But Steba’s Tookad Falls Hard At US FDA Panel

Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.


UK Sunscreen Claims On ‘Negligible’ Difference In SPF Strengths Don't Add Up

Advertising Standards Authority says Green People Co. misled consumers with claims SPF 30 formulas filter out only 1% less UVB rays than SPF 50, trying to draw a negligible difference between the formulas. The claims appeared in a direct mailer and on the brand’s website in July 2019.

Topics

UsernamePublicRestriction

Register

PS002716

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel